Mayer Lawrence D, Janoff Andrew S
Celator Pharmaceuticals, 1779 West Seventy-fifth Avenue, Vancouver BC V6P 6P2.
Mol Interv. 2007 Aug;7(4):216-23. doi: 10.1124/mi.7.4.8.
Cancer chemotherapy treatments typically employ drug combinations in which the dose of each agent is pushed to the brink of unacceptable toxicity; however, emerging evidence indicates that this approach may not be providing optimal efficacy due to the manner in which drugs interact. Specifically, whereas certain ratios of combined drugs can be synergistic, other ratios of the same agents may be antagonistic, implying that the most efficacious combinations may be those that utilize certain agents at reduced doses. Advances in nano-scale drug delivery vehicles now enable the translation of in vitro information on synergistic drug ratios into improved anticancer combination therapies in which the desired drug ratio can be controlled and maintained following administration in vivo, so that synergistic effects can be exploited. This "ratiometric" approach to combination chemotherapy opens new opportunities to enhance the effectiveness of existing and future treatment regimens across a spectrum of human diseases.
癌症化疗通常采用联合用药，每种药物的剂量都被推到了难以接受的毒性边缘；然而，新出现的证据表明，由于药物相互作用的方式，这种方法可能无法提供最佳疗效。具体而言，虽然某些联合药物的比例可能具有协同作用，但相同药物的其他比例可能具有拮抗作用，这意味着最有效的联合用药可能是那些以较低剂量使用某些药物的组合。纳米级药物递送载体的进展现在能够将体外关于协同药物比例的信息转化为改进的抗癌联合疗法，在这种疗法中，所需的药物比例在体内给药后可以得到控制和维持，从而可以利用协同效应。这种联合化疗的“比例法”为提高现有和未来治疗方案对一系列人类疾病的有效性开辟了新机会。
